| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 245.28K | 370.65K | 943.7K | 1.42M | 2.08M | 2.09M | 2.14M |
| Revenue Growth % | - | - | - | - | 0.51% | 1.55% | 0.51% | 0.46% | 0% | 0.03% |
| Cost of Goods Sold | 0 | 0 | 0 | 288.3K | 549.11K | 582.38K | 917.84K | 1.33M | 1.22M | 1.44M |
| COGS % of Revenue | - | - | - | 1.18% | 1.48% | 0.62% | 0.65% | 0.64% | 0.59% | 0.67% |
| Gross Profit | 0 | 0 | 0 | -43.02K | -178.46K | 361.32K | 504.31K | 750.41K | 862.11K | 699.3K |
| Gross Margin % | - | - | - | -0.18% | -0.48% | 0.38% | 0.35% | 0.36% | 0.41% | 0.33% |
| Gross Profit Growth % | - | - | - | - | -3.15% | 3.02% | 0.4% | 0.49% | 0.15% | -0.19% |
| Operating Expenses | 400 | 151.26K | 171.95K | 3.29M | 1.79M | 2.96M | 4.43M | 4.9M | 5.73M | 7.39M |
| OpEx % of Revenue | - | - | - | 13.41% | 4.83% | 3.13% | 3.12% | 2.36% | 2.75% | 3.45% |
| Selling, General & Admin | 400 | 151.26K | 171.95K | 3.29M | 1.79M | 2.96M | 4.02M | 3.92M | 3.77M | 4.27M |
| SG&A % of Revenue | - | - | - | 13.41% | 4.83% | 3.13% | 2.83% | 1.88% | 1.81% | 2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 411.38K | 982.23K | 1.96M | 3.12M |
| R&D % of Revenue | - | - | - | - | - | - | 0.29% | 0.47% | 0.94% | 1.46% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -400 | -151.26K | -171.95K | -3.33M | -1.97M | -2.6M | -3.93M | -4.15M | -4.87M | -6.69M |
| Operating Margin % | - | - | - | -13.58% | -5.31% | -2.75% | -2.76% | -1.99% | -2.34% | -3.13% |
| Operating Income Growth % | - | -377.15% | -0.14% | -18.37% | 0.41% | -0.32% | -0.51% | -0.06% | -0.17% | -0.37% |
| EBITDA | 4.4K | 0 | -24.69K | -3.29M | -1.88M | -2.43M | -3.61M | -3.78M | -4.58M | -6.4M |
| EBITDA Margin % | - | - | - | -13.43% | -5.07% | -2.57% | -2.54% | -1.82% | -2.2% | -2.99% |
| EBITDA Growth % | - | -1% | - | -132.45% | 0.43% | -0.29% | -0.49% | -0.05% | -0.21% | -0.4% |
| D&A (Non-Cash Add-back) | 4.8K | 151.26K | 147.26K | 37.01K | 91.84K | 169.72K | 318.26K | 368.96K | 287.72K | 285.05K |
| EBIT | 0 | -151.26K | -2.67M | -3.33M | -2.65M | -2.65M | -6.06M | -4.48M | -5.41M | -10.46M |
| Net Interest Income | 0 | 0 | 0 | 0 | -73.41K | -349.82K | -118.42K | -8.29K | -58.97K | 170.26K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 280.69K | 0 | 0 | 16.85K | 191.67K |
| Interest Expense | 0 | 0 | 0 | 0 | 73.41K | 280.69K | 118.42K | 8.29K | 75.81K | 21.41K |
| Other Income/Expense | 0 | 0 | -2.5M | 0 | -752.19K | -336.88K | -2.25M | -335.62K | -613.39K | -3.79M |
| Pretax Income | -400 | -151.26K | -2.67M | -3.33M | -2.72M | -2.93M | -6.18M | -4.48M | -5.49M | -10.48M |
| Pretax Margin % | - | - | - | -13.58% | -7.34% | -3.11% | -4.34% | -2.16% | -2.63% | -4.9% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1.03% | 1.1% | 1.36% | 1.07% | 1% | 1% |
| Net Income | -400 | -151.26K | -2.67M | -3.33M | -2.8M | -3.21M | -8.42M | -4.81M | -5.49M | -10.48M |
| Net Margin % | - | - | - | -13.58% | -7.54% | -3.41% | -5.92% | -2.31% | -2.63% | -4.9% |
| Net Income Growth % | - | -377.15% | -16.66% | -0.25% | 0.16% | -0.15% | -1.62% | 0.43% | -0.14% | -0.91% |
| Net Income (Continuing) | -400 | -151.26K | -2.67M | -3.33M | -2.72M | -2.93M | -6.18M | -4.48M | -5.49M | -10.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | -0.03 | -0.48 | -0.53 | -0.44 | -0.48 | -1.06 | -0.57 | -0.69 | -0.99 |
| EPS Growth % | - | - | -18.2% | -0.1% | 0.17% | -0.09% | -1.21% | 0.46% | -0.21% | -0.43% |
| EPS (Basic) | -0.00 | -0.03 | -0.48 | -0.53 | -0.44 | -0.48 | -1.06 | -0.57 | -0.69 | -0.99 |
| Diluted Shares Outstanding | 6.06M | 6.06M | 5.6M | 6.24M | 6.33M | 6.73M | 7.93M | 8.46M | 7.95M | 10.61M |
| Basic Shares Outstanding | 6.06M | 6.06M | 5.6M | 6.24M | 6.33M | 6.73M | 7.93M | 8.46M | 7.95M | 10.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 330 | 37.73K | 164.9K | 590.47K | 43.18K | 314.19K | 5.47M | 2.69M | 1.02M | 4.79M |
| Cash & Short-Term Investments | 100 | 27.12K | 0 | 474.65K | 10.18K | 151.99K | 4.89M | 1.99M | 492.94K | 4.31M |
| Cash Only | 100 | 27.12K | 0 | 474.65K | 10.18K | 151.99K | 4.89M | 1.99M | 492.94K | 4.31M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 230 | 229 | 263 | 13.09K | 12.83K | 109.35K | 71.38K | 113.05K | 148.65K | 73.85K |
| Days Sales Outstanding | - | - | - | 19.48 | 12.64 | 42.29 | 18.32 | 19.84 | 26.02 | 12.6 |
| Inventory | 0 | 8.05K | 4.13K | 0 | 0 | 52.85K | 131.65K | 229.34K | 168.6K | 212.04K |
| Days Inventory Outstanding | - | - | - | - | 0 | 33.12 | 52.35 | 62.98 | 50.31 | 53.75 |
| Other Current Assets | 0 | 0 | 0 | 102.72K | 0 | 0 | 370.47K | 0 | 0 | -546 |
| Total Non-Current Assets | 0 | 0 | 0 | 2.22M | 2.15M | 9.61M | 7.27M | 6.76M | 6.5M | 2.68M |
| Property, Plant & Equipment | 0 | 0 | 0 | 146.15K | 120.64K | 1.08M | 998.34K | 960.49K | 806.3K | 695.06K |
| Fixed Asset Turnover | - | - | - | 1.68x | 3.07x | 0.88x | 1.42x | 2.17x | 2.59x | 3.08x |
| Goodwill | 0 | 0 | 0 | 1.72M | 1.72M | 7.53M | 5.35M | 5.02M | 5.02M | 1.72M |
| Intangible Assets | 0 | 0 | 0 | 351.77K | 314.7K | 1.01M | 926.91K | 780.43K | 667.28K | 261.09K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | -7.27M | -6.76M | 0 | -63 |
| Total Assets | 330 | 37.73K | 164.9K | 2.81M | 2.2M | 9.93M | 12.74M | 9.46M | 7.52M | 7.47M |
| Asset Turnover | - | - | - | 0.09x | 0.17x | 0.10x | 0.11x | 0.22x | 0.28x | 0.29x |
| Asset Growth % | - | 113.32% | 3.37% | 16.03% | -0.22% | 3.52% | 0.28% | -0.26% | -0.21% | -0.01% |
| Total Current Liabilities | 11.11K | 14.62K | 43.39K | 403.01K | 2.02M | 2.57M | 779.26K | 748.61K | 999.09K | 982.85K |
| Accounts Payable | 1.2K | 4.15K | 12.34K | 291.78K | 771.93K | 940.61K | 639.54K | 534.68K | 680.13K | 698.82K |
| Days Payables Outstanding | - | - | - | 369.41 | 513.11 | 589.52 | 254.33 | 146.82 | 202.95 | 177.13 |
| Short-Term Debt | 9.91K | 10.47K | 31.05K | 40K | 311.57K | 1.54M | 33.45K | 51.03K | 127.18K | 128.14K |
| Deferred Revenue (Current) | 0 | 0 | -43.39K | 71.22K | 0 | 86.85K | 106.27K | 162.9K | 157.5K | 155.88K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 928.77K | -24.74K | -19.33K | -31.29K | 0 | 0 |
| Current Ratio | 0.03x | 2.58x | 3.80x | 1.47x | 0.02x | 0.12x | 7.01x | 3.60x | 1.02x | 4.88x |
| Quick Ratio | 0.03x | 2.03x | 3.71x | 1.47x | 0.02x | 0.10x | 6.84x | 3.29x | 0.85x | 4.66x |
| Cash Conversion Cycle | - | - | - | - | -500.48 | -514.11 | -183.65 | -64.01 | -126.62 | -110.79 |
| Total Non-Current Liabilities | 686 | 0 | 0 | 0 | 0 | 246.87K | 101.12K | 134.77K | 79.83K | 58.2K |
| Long-Term Debt | 686 | 0 | 0 | 0 | 0 | 246.87K | 101.12K | 100.5K | 79.83K | 58.2K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 96.8K | 0 | 34.28K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | -96.8K | 0 | 0 | 0 | 0 |
| Total Liabilities | 11.8K | 14.62K | 43.39K | 403.01K | 2.02M | 2.82M | 880.38K | 883.39K | 1.08M | 1.04M |
| Total Debt | 10.6K | 10.47K | 31.05K | 40K | 321.62K | 1.79M | 134.57K | 185.81K | 241.28K | 186.35K |
| Net Debt | 10.5K | -16.66K | 31.05K | -434.65K | 311.44K | 1.64M | -4.76M | -1.8M | -251.66K | -4.13M |
| Debt / Equity | - | 0.45x | 0.26x | 0.02x | 1.83x | 0.25x | 0.01x | 0.02x | 0.04x | 0.03x |
| Debt / EBITDA | 2.41x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.39x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -26.83x | -9.25x | -33.19x | -500.41x | -64.26x | -312.51x |
| Total Equity | -11.47K | 23.11K | 121.51K | 2.4M | 175.43K | 7.11M | 11.86M | 8.57M | 6.44M | 6.43M |
| Equity Growth % | - | 3.01% | 4.26% | 18.79% | -0.93% | 39.54% | 0.67% | -0.28% | -0.25% | -0% |
| Book Value per Share | -0.00 | 0.00 | 0.02 | 0.39 | 0.03 | 1.06 | 1.49 | 1.01 | 0.81 | 0.61 |
| Total Shareholders' Equity | -11.47K | 23.11K | 121.51K | 2.4M | 175.43K | 7.11M | 11.86M | 8.57M | 6.44M | 6.43M |
| Common Stock | 21.88K | 15.57K | 20.88K | 21.7K | 5.44K | 6.26K | 7.84K | 7.83K | 8.86K | 11.07K |
| Retained Earnings | -26.2K | -177.46K | -2.85M | -6.18M | -8.9M | -11.84M | -18.01M | -22.49M | -27.98M | -38.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -104.47K | -32.64K | -32.64K | -149K |
| Accumulated OCI | 1.64K | 1.71K | -446 | -52 | -304 | -304 | -304 | -304 | -304 | -304 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 0 | -147.92K | -92.86K | -1.11M | -894.47K | -297.06K | -2.81M | -2.99M | -3.53M | -4.63M |
| Operating CF Margin % | - | - | - | -4.51% | -2.41% | -0.31% | -1.98% | -1.44% | -1.69% | -2.16% |
| Operating CF Growth % | - | - | 0.37% | -10.9% | 0.19% | 0.67% | -8.46% | -0.06% | -0.18% | -0.31% |
| Net Income | -400 | -151.26K | -2.67M | -3.33M | -2.72M | -2.93M | -6.18M | -4.48M | -5.49M | -10.48M |
| Depreciation & Amortization | 0 | 0 | 0 | 37.01K | 91.41K | 169.72K | 318.26K | 368.96K | 287.72K | 285.05K |
| Stock-Based Compensation | 0 | 7.77K | 0 | 1.76M | 252.7K | 2M | 897.83K | 732.13K | 742.7K | 1.54M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 678.77K | -12.93K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.8K | 15.82K | 2.5M | 24.3K | 91.32K | 363.89K | 2.23M | 614.51K | 704.17K | 3.99M |
| Working Capital Changes | 400 | -4.43K | 75.09K | 400.51K | 712.96K | 110.23K | -541.38K | -219.32K | 223.22K | 34.09K |
| Change in Receivables | 0 | 0 | 0 | -12.82K | 255 | -94.75K | 42.97K | -41.66K | -153.97K | 74.8K |
| Change in Inventory | 0 | -8.05K | 3.92K | 4.13K | -720.15K | -10.23K | -78.8K | -97.69K | 60.73K | -43.44K |
| Change in Payables | 0 | 0 | 4K | 337.98K | 720.15K | 155.22K | -145.26K | -104.86K | 198.89K | 23.61K |
| Cash from Investing | 0 | 0 | 92.89K | -404.16K | 0 | 66.99K | -81.59K | -79.3K | -51.76K | -92.04K |
| Capital Expenditures | 0 | 0 | 0 | -4.16K | 0 | 0 | -81.59K | -79.3K | -51.76K | -92.04K |
| CapEx % of Revenue | - | - | - | 0.02% | - | - | 0.06% | 0.04% | 0.02% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -404.16K | 0 | 66.99K | -81.59K | -79.3K | 0 | 0 |
| Cash from Financing | 100 | 174.9K | 65.76K | 1.98M | 430.25K | 371.87K | 7.63M | 160.07K | 2.09M | 8.54M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -196.59K | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -100 | 8.25K | 461.47K | 5.25K | 18.31K | 3.14M | 296.88K | 0 | 69 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 0 | -147.92K | -92.86K | -1.11M | -894.47K | -297.06K | -2.89M | -3.07M | -3.58M | -4.72M |
| FCF Margin % | - | - | - | -4.52% | -2.41% | -0.31% | -2.03% | -1.47% | -1.72% | -2.21% |
| FCF Growth % | - | - | 0.37% | -10.95% | 0.19% | 0.67% | -8.73% | -0.06% | -0.17% | -0.32% |
| FCF per Share | - | -0.02 | -0.02 | -0.18 | -0.14 | -0.04 | -0.36 | -0.36 | -0.45 | -0.44 |
| FCF Conversion (FCF/Net Income) | - | 0.98x | 0.03x | 0.33x | 0.32x | 0.09x | 0.33x | 0.62x | 0.64x | 0.44x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -2599.19% | -3695.2% | -263.74% | -216.67% | -88.19% | -88.79% | -47.09% | -73.08% | -162.94% |
| Return on Invested Capital (ROIC) | - | -4136.55% | -162.2% | -235.42% | -120.24% | -42.17% | -37.19% | -44.84% | -56.39% | -118.2% |
| Gross Margin | - | - | - | -17.54% | -48.15% | 38.29% | 35.46% | 36.08% | 41.34% | 32.68% |
| Net Margin | - | - | - | -1358.11% | -754.1% | -340.52% | -592.23% | -231.33% | -263.05% | -489.86% |
| Debt / Equity | - | 0.45x | 0.26x | 0.02x | 1.83x | 0.25x | 0.01x | 0.02x | 0.04x | 0.03x |
| Interest Coverage | - | - | - | - | -26.83x | -9.25x | -33.19x | -500.41x | -64.26x | -312.51x |
| FCF Conversion | - | 0.98x | 0.03x | 0.33x | 0.32x | 0.09x | 0.33x | 0.62x | 0.64x | 0.44x |
| Revenue Growth | - | - | - | - | 51.11% | 154.61% | 50.7% | 46.23% | 0.27% | 2.62% |
| 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| UNITED STATES | 196.28K | 245.68K | - | 2.08M | 2.09M | 2.14M |
| UNITED STATES Growth | - | 25.16% | - | - | 0.27% | 2.60% |
| Non-US | 49K | 124.96K | 583.32K | - | - | - |
| Non-US Growth | - | 155.02% | 366.82% | - | - | - |
Nutriband Inc. (NTRB) reported $2.3M in revenue for fiscal year 2024.
Nutriband Inc. (NTRB) grew revenue by 2.6% over the past year. Growth has been modest.
Nutriband Inc. (NTRB) reported a net loss of $12.8M for fiscal year 2024.
Nutriband Inc. (NTRB) has a return on equity (ROE) of -162.9%. Negative ROE indicates the company is unprofitable.
Nutriband Inc. (NTRB) had negative free cash flow of $5.6M in fiscal year 2024, likely due to heavy capital investments.